Literature DB >> 24976643

Influence of Iron Oxide Nanoparticles on Innate and Genetically Modified Secretion Profiles of Mesenchymal Stem Cells.

Abu Emran Bashar1, Andrew Metcalfe1, Anat Yanai1, Christopher Laver1, Urs O Häfeli2, Cheryl Y Gregory-Evans1, Orson L Moritz1, Joanne A Matsubara1, Kevin Gregory-Evans1.   

Abstract

Mesenchymal stem cells (MSCs) have well-established paracrine effects that are proving to be therapeutically useful. This potential is based on the ability of MSCs to secrete a range of neuroprotective and anti-inflammatory molecules. Previous work in our laboratory has demonstrated that intravenous injection of MSCs, treated with superparamagnetic iron oxide nanoparticle fluidMAG-D resulted in enhanced levels of glial-derived neurotrophic factor, ciliary neurotrophic factor, hepatocyte growth factor and interleukin-10 in the dystrophic rat retina. In this present study we investigated whether the concentration of fluidMAG-D in cell culture media affects the secretion of these four molecules in vitro. In addition, we assessed the effect of fluidMAG-D concentration on retinoschisin secretion from genetically modified MSCs. ELISA-assayed secretion of these molecules was measured using escalating concentrations of fluidMAG-D which resulted in MSC iron loads of 0, 7, 120, or 274 pg iron oxide per cell respectively. Our results demonstrated glial-derived neurotrophic factor and hepatocyte growth factor secretion was significantly decreased but only at the 96 hour's time-point whereas no statistically significant effect was seen with ciliary neurotrophic factor secretion. Whereas no effect was observed on culture media concentrations of retinoschisin with increasing iron oxide load, a statistically significant increase in cell lysate retinoschisin concentration (p = 0.01) was observed suggesting that increasing fluidMAG-D concentration did increase retinoschisin production but this did not lead to greater secretion. We hypothesize that higher concentrations of iron-oxide nanoparticle fluidMAG-D have an effect on the innate ability of MSCs to secrete therapeutically useful molecules and also on secretion from genetically modified cells. Further work is required to verify these in vitro finding using in vivo model systems.

Entities:  

Keywords:  Blindness; magnetic nanoparticles; retina; stem cells

Year:  2013        PMID: 24976643      PMCID: PMC4072646          DOI: 10.1109/TMAG.2012.2225829

Source DB:  PubMed          Journal:  IEEE Trans Magn        ISSN: 0018-9464            Impact factor:   1.700


  21 in total

1.  Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles.

Authors:  Anat Yanai; Urs O Häfeli; Andrew L Metcalfe; Peter Soema; Lois Addo; Cheryl Y Gregory-Evans; Kelvin Po; Xianghong Shan; Orson L Moritz; Kevin Gregory-Evans
Journal:  Cell Transplant       Date:  2012-03-08       Impact factor: 4.064

Review 2.  Ex vivo gene therapy and vision.

Authors:  Kevin Gregory-Evans; A M A Emran Bashar; Malcolm Tan
Journal:  Curr Gene Ther       Date:  2012-04-01       Impact factor: 4.391

Review 3.  Mesenchymal stem cells and potential applications in treating ocular disease.

Authors:  Aaron W Joe; Kevin Gregory-Evans
Journal:  Curr Eye Res       Date:  2010-11       Impact factor: 2.424

4.  Endoplasmic reticulum stress signals in defined human embryonic stem cell lines and culture conditions.

Authors:  Miguel Angel Blanco-Gelaz; Beatriz Suarez-Alvarez; Gertrudis Ligero; Laura Sanchez; Jose Ramon Vidal-Castiñeira; Eliecer Coto; Harry Moore; Pablo Menendez; Carlos Lopez-Larrea
Journal:  Stem Cell Rev Rep       Date:  2010-09       Impact factor: 5.739

5.  Superparamagnetic iron oxide nanoparticles change endothelial cell morphology and mechanics via reactive oxygen species formation.

Authors:  Kivilcim Buyukhatipoglu; Alisa Morss Clyne
Journal:  J Biomed Mater Res A       Date:  2010-11-09       Impact factor: 4.396

6.  Retinoschisin is a peripheral membrane protein with affinity for anionic phospholipids and affected by divalent cations.

Authors:  Camasamudram Vijayasarathy; Yuichiro Takada; Yong Zeng; Ronald A Bush; Paul A Sieving
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-03       Impact factor: 4.799

7.  Causes of visual impairment in people aged 75 years and older in Britain: an add-on study to the MRC Trial of Assessment and Management of Older People in the Community.

Authors:  J R Evans; A E Fletcher; R P L Wormald
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

8.  Superparamagnetic iron oxide nanoparticles labeling of bone marrow stromal (mesenchymal) cells does not affect their "stemness".

Authors:  Arun Balakumaran; Edyta Pawelczyk; Jiaqiang Ren; Brian Sworder; Aneeka Chaudhry; Marianna Sabatino; David Stroncek; Joseph A Frank; Pamela G Robey
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

9.  Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles.

Authors:  Michael R Loebinger; Panagiotis G Kyrtatos; Mark Turmaine; Anthony N Price; Quentin Pankhurst; Mark F Lythgoe; Sam M Janes
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

10.  Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress.

Authors:  Saba Naqvi; Mohammad Samim; Mz Abdin; Farhan Jalees Ahmed; An Maitra; Ck Prashant; Amit K Dinda
Journal:  Int J Nanomedicine       Date:  2010-11-16
View more
  2 in total

1.  An ex vivo gene therapy approach in X-linked retinoschisis.

Authors:  Abu E Bashar; Andrew L Metcalfe; Ishaq A Viringipurampeer; Anat Yanai; Cheryl Y Gregory-Evans; Kevin Gregory-Evans
Journal:  Mol Vis       Date:  2016-06-24       Impact factor: 2.367

2.  Labeling of human mesenchymal stem cells with different classes of vital stains: robustness and toxicity.

Authors:  Anna Andrzejewska; Anna Jablonska; Martyna Seta; Sylwia Dabrowska; Piotr Walczak; Miroslaw Janowski; Barbara Lukomska
Journal:  Stem Cell Res Ther       Date:  2019-06-25       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.